A Retrospective Real-World Study Based on RATIONALE-307

Recruiting now

Conditions studied: NSCLC (Advanced Non-small Cell Lung Cancer)

In brief

The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.

Key facts

Study ID

NCT07478809

Run by

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

People needed

109

Starts

2026-02-28

Expected to finish

2027-12-31

Last updated by the study team

2026-03-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion

You may not qualify if…

• Patients who had a documented death before study completion in the RATIONALE-307 trial

Where it is running

• National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.